Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT V560_Y578del |
| Therapy | Ponatinib |
| Indication/Tumor Type | gastrointestinal stromal tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT V560_Y578del | gastrointestinal stromal tumor | sensitive | Ponatinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608). | 25239608 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25239608) | Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. | Full reference... |